Rank which trial candidates to sequence first for a target mutation, so a sponsor fills an NPM1-defined cohort with fewer assays and a signed record of every selection. It ranks, it never decides; sequencing always confirms; a recall floor bounds what it can miss.
Research-use todayA signed assessment that evolves from day zero to final molecular: a provisional read while sequencing runs, an ELN-2022 risk class, and a therapy-eligibility map, each claim tied to the signal that triggered it. Decision support that defers the hard calls to molecular and the clinician.
On a De Novo device pathwayWe are looking for clinical and pharma design partners in hematology. If you run acute myeloid leukemia trials or hold aligned multimodal data, we would like to talk.